Key facts
- Delfi Diagnostics’s last known valuation is $725.0M (Jun 2024).
- It has raised $465.9M across 1 recorded rounds; the latest was Later Stage VC ($34.3M) in Dec 2025.
- Notable investors include Menlo Ventures, OrbiMed, Mirae Asset Capital, Point72 Ventures, T. Rowe Price Group — 27 tracked in total.
- Delfi Diagnostics has filed 1 Form D with the SEC, most recently Dec 2025 ($34.3M sold to 50 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Delfi Diagnostics
Funding rounds
1 roundsAbout Delfi Diagnostics
Developer of a blood test system designed for the early detection of cancer. The company's medical system uses machine learning to specialize in the research and development of innovative blood and genome testing for the detection and interception of cancer when it is curable, enabling healthcare professionals to detect previously unrecognized cancer-associated cell-free DNA fragments and provide efficient treatments for a speedy recovery.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2019
- Employees
- 175
- Website
- delfidiagnostics.com/
- Ownership
- Privately Held (backing)
Delfi Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delfi Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delfi Diagnostics in its N-PORT filings yet. We sweep new filings monthly.